Steven Cohen’s Inovio Pharmaceuticals INO Stock Holding History

Steven Cohen’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,083	Closed	-$290K	–	1017
2020 Q3	$290K	Buy	+2,083	New	+$434K	﹤0.01%	853

Other funds holding INO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Steven Cohen's INO Position: Q4 2023 in Review

Steven Cohen sold out of Inovio Pharmaceuticals (INO) in Q4 2023, closing a stake of 6,674 shares — an estimated $31.2K sold.

Steven Cohen first reported a position in INO in Q1 2023 and held it in 3 quarters. The position peaked at $70K in Q1 2023. 113 funds tracked by Wall St. Rank hold INO as of Q4 2023.

Steven Cohen reported no remaining Inovio Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Steven Cohen sold 6,674 Inovio Pharmaceuticals shares in Q4 2023, an estimated $31.2K.
Steven Cohen first reported a position in Inovio Pharmaceuticals in Q1 2023 and held it in 3 quarters.
Steven Cohen's Inovio Pharmaceuticals position peaked at $70K in Q1 2023.
113 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2023.

Based on Point72 Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.